http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105343121-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 |
| filingDate | 2015-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105343121-B |
| titleOfInvention | Application of polyguluronic acid sulfate in the preparation of anti-hepatitis B virus medicine |
| abstract | The invention provides the application of polyguluronic acid sulfate in the preparation of anti-hepatitis B virus medicine. The present invention not only proves that polyguluronic acid sulfate has a good inhibitory effect on the expression of HBV surface antigen HBsAg and HBV e antigen HBeAg in the liver cancer cell line HepG2.2.15, but also can significantly inhibit the expression of HBV S mRNA in Expression in the HepG2.2.15 cell line can enhance the production and secretion of IFN-β in cells, and activate the NF-κB and MAPK signaling pathways related to anti-virus immunity. The polyguluronic acid sulfate provided by the present invention is a marine sulfated polysaccharide compound, which has many advantages such as abundant resources, low cost and high safety, and its anti-HBV effect is obviously better than that of the positive control drug lamivudine. It has broad application prospects in the preparation of anti-hepatitis B virus drugs. |
| priorityDate | 2015-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 147.